Selective cell therapy for the treatment of renal failure
AssigneeWake Forest University Health Sciences
InventorsAnthony Atala, James J. Yoo
Life of this patent
Estimating the term…
Abstract
Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells produce EPO in vivo.
Claims11
-35. (canceled)
A method of selecting erythropoietin (EPO) producing cells, said method comprising the steps of:
- (a) providing a heterogeneous suspension of kidney cells;
- (b) centrifuging the heterogeneous suspension to form a cell pellet;
- (c) adding to the cell pellet a solution comprising a primary antibody that binds to EPO to form a first antibody-bound cell solution;
- (d) adding to the first antibody-bound cell solution a solution comprising a secondary antibody that binds to the primary antibody to form a second antibody-bound solution, wherein the secondary antibody is covalently bound to a magnetic microbead;
- and
- (e) selecting the EPO producing cells from the second antibody-bound solution using a magnet.
Dependencies are inferred from the claim text.